Actively Recruiting
Study of Blood-Based Markers to Detect Recurrence in Colorectal Cancer Tracking Tumor DNA and Proteins After Treatment for Up to 5 Years
Led by M.D. Anderson Cancer Center · Updated on 2026-05-29
1000
Participants Needed
10
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating whether circulating tumor DNA ctDNA and other tumor-related molecules in the blood can help predict if colorectal cancer will return or spread. This study focuses on analyzing cancer-specific DNA, RNA, and protein changes in the blood to improve understanding of cancer recurrence after treatment. It aims to monitor these markers over time and assess their relationship to patient outcomes such as disease-free and overall survival. Participants will have blood samples collected at several key times before treatment, during neoadjuvant therapy, before surgery, and up to four times yearly for five years. Tissue samples will also be collected during surgical tumor removal. Medical records will be reviewed to support the study. The study does not involve experimental treatments but collects biospecimens and health data to understand cancer markers. During the study, participants will provide blood and tissue samples and allow review of their medical records. Researchers will analyze changes in cancer-specific DNA, RNA, and proteins in plasma over up to five years. The main outcomes include detecting cancer recurrence and analyzing molecular changes during and after treatment. This long-term monitoring aims to improve early detection of cancer return and survival predictions.
CONDITIONS
Brief Title
Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study
Research Team
A
Arvind Dasari
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here